Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.

The oncologist - 1 Jan 2021

Jardim Denis L, Millis Sherri Z, Ross Jeffrey S, Woo Michelle Sue-Ann, Ali Siraj M, Kurzrock Razelle

Abstract excerpt

BACKGROUND: We describe the landscape of cyclin and interactive gene pathway alterations in 190,247 solid tumors. METHODS: Using comprehensive genomic profiling (315 genes, >500× coverage), samples were analyzed for alterations in activating/sensitizing cyclin genes (CDK4 amplification, CDK6 amplification, CCND1, CCND2, CCND3, CDKN2B [loss], CDKN2A [loss], SMARCB1), hormone genes (estrogen receptor 1 [ESR1],...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCND2 gene
Share to CCNE1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to RB1 gene

Share to Genomics

Share to Glioma

Share to Mutation

Share to Neoplasms, Germ Cell and Embryonal

Share to Testicular Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32885893
DOI: 10.1634/theoncologist.2020-0509
PMCID: PMC7794175

Genes

AR
ESR1
CCND1
CCND2
CCNE1
CDK4
CDKN2A
CDKN2B
RB1
SMARCB1
CCND3
CDK6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.PMID 32885893Read ↗

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics.Semantic proximity Read ↗

Cyclin alterations in diverse cancers: Outcome and co-amplification network.Semantic proximity Read ↗

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristicsSemantic proximity Read ↗

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilitiesSemantic proximity Read ↗

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.Semantic proximity Read ↗

Genomic Divergence Between Matched Primary and Metastatic Tumors Across Cancer Types: A Pan-Cancer Analysis of 5,692 SamplesSemantic proximity Read ↗

Integrative multi-omics analysis reveals the landscape of Cyclin-Dependent Kinase (CDK) family genes in pan-cancerSemantic proximity Read ↗

Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas.Semantic proximity Read ↗

Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment ParadigmsSemantic proximity Read ↗

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics.Semantic proximity Read ↗

An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.